Phenotypic switching prevention and proliferation/migration inhibition of vascular smooth muscle cells by the ruthenium nitrosyl complex trans-[Ru(NO)Cl(cyclam](PF6)2
Autor: | Elia Tfouni, Mariana G. de Oliveira, Fábio Gorzoni Doro, Marta Helena Krieger |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Pharmacology Vascular smooth muscle Intimal hyperplasia Chemistry Cell growth Growth factor medicine.medical_treatment Phenotypic switching Cell Pharmaceutical Science 030204 cardiovascular system & hematology medicine.disease Cell biology Nitric oxide 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Biochemistry medicine Actin |
Zdroj: | Journal of Pharmacy and Pharmacology. 69:1155-1165 |
ISSN: | 2042-7158 0022-3573 |
Popis: | Objectives Vascular smooth muscle cell (VSMC) migration and proliferation at sites of vascular injury are both critical steps in the development of intimal hyperplasia (IH). Local delivery of nitric oxide (NO) largely prevents these events. Among the NO donors, tetraazamacrocyclic nitrosyl complexes, such as trans-[Ru(NO)Cl(cyclam)](PF6)2 (cyclamNO), gained attention for their features, which include the possibility of being embedded in solid matrices, and ability to participate in a nitrite/NO catalytic conversion cycle. Methods Methods used to evaluate cyclamNO activity: safety margin by NR and MTT; cell proliferation by 3H-thymidine incorporation and proliferating cell nuclear antigen (PCNA) expression; antimigratory properties by transwell and wound healing; prevention of cell phenotypic switching under platelet-derived growth factor type BB (PDGF-BB) stimuli by analysis of alpha smooth muscle actin (α-SMA) expression. Key findings Cell proliferation and migration induced by PDGF-BB were significantly inhibited by cyclamNO. The ~60% reduction on expression of contractile protein α-SMA induced by PDGF-BB revealed VSMC phenotypic switching which is significantly prevented by cyclamNO. Compared to the NO donor sodium nitroprusside, cyclamNO showed to be significantly less cytotoxic. Conclusions With great potential to maintain VSMC functionality and prevent IH-associated events, cyclamNO might be a promissory drug for several applications in cardiovascular medicine, as in stents. |
Databáze: | OpenAIRE |
Externí odkaz: |